Analysis of risk factors for multiple primary oral squamous cell carcinoma: a cohort study

Lin, Xiaoyu; Wu, Xiaoxia; Gomaa, A; Chen, Jie; Wu, Limeng; Xie, Xiaoyue; Hu, Yibo; Jiang, Canhua

doi:10.1007/s00784-019-03189-0

Cited by 14 publications

(19 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their results showed that arecoline may result to relatively overexpress in OSF tissues compared to normal tissue counterparts and can activate BMFs, which may be one of the pathogenic pathways of OSF. Lin et al [ 51 ] found that OSF associated with chewing betel nut increases the chance of multiple oral cancers greatly. It is vital to prevent OSF and stop chewing betel nut for reducing the morbidity of OC.…”

Section: Toxicological Effectsmentioning

confidence: 99%

Chemical Composition, Pharmacological, and Toxicological Effects of Betel Nut

Chen

Deng

2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Betel nut, the fruit of Areca catechu L, has a long medical history in Southeast Asia. It is native to Malaysia and is cultivated and processed extensively in subtropical regions, such as South China and India. Betel nut almost appears as a “snack” in various occasions in most parts of China. Clinically, betel nut can play a certain pharmacology role and was used in malaria, ascariasis, arthritis, enterozoic abdominalgia, stagnation of food, diarrhea, edema, and beriberi. The nervous excitement of betel nut chewing has made it gradually become popular. However, chewing betel nut can induce oral submucosal fibrosis (OSF) and oral cancer (OC). At the same time, long-term chewing of betel nut also causes inhaled asthma, sperm reducing, betel quid dependence (BQD), and uterine and esophageal cancers. The main components of processed betel nut are the goal of this review. This study will mainly start from the pharmacological activity and toxicology study of betel nut in recent years, aiming to seek its advantages and disadvantages. In the meantime, this study will analyze and emphasize that betel nut and arecoline are the high-risk factors for oral cancer, which should arouse attention and vigilance of the public.

show abstract

Section: Toxicological Effectsmentioning

confidence: 99%

Chemical Composition, Pharmacological, and Toxicological Effects of Betel Nut

Chen

Deng

2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Second, another possible reason lies in the fact that OC patients who habitually chewed BQ‐AN have high incidences of local recurrences, second and even primary tumors, which were considered as the major causes of death and poor prognosis for OC patients (Liao et al., 2006, 2014; Lin et al., 2020). Liao et al reported that BQ‐AN chewers with OC have a higher risk for local recurrences and second primary tumors after surgical treatment compared with non‐chewers (Liao et al., 2007, 2008).…”

Section: Discussionmentioning

confidence: 99%

“…Liao et al reported that BQ‐AN chewers with OC have a higher risk for local recurrences and second primary tumors after surgical treatment compared with non‐chewers (Liao et al., 2007, 2008). Also, Lin et al found that BQ‐AN chewing and related OSF were the independent risk factors for multiple primary OC (Lin et al., 2020). The effects of field cancerization may interpret the cause of higher than expected incidences of local recurrences and second primary tumors (Simple, Suresh, Das, & Kuriakose, 2015).…”

Section: Discussionmentioning

confidence: 99%

“…In addition, due to the high incidence of local recurrences and second primary tumors in patients with a BQ‐AN chewing habit (Liao et al., 2007, 2008), a more intimate follow‐up should be applied to detect the diseases in time. Lin et al reported that the mean interval from primary to secondary lesion detection in patients with second primary OC was 37 months (range, 6–98 months; Lin et al., 2020), and thus, a long‐term follow‐up (more than 5 years) should be also underlined and recommended in BQ‐AN‐related OC patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Do betel quid and areca nut chewing deteriorate prognosis of oral cancer? A systematic review, meta‐analysis, and research agenda

et al. 2020

View full text Add to dashboard Cite

Objective To explore the correlations between the habit of betel quid and areca nut (BQ‐AN) chewing and the prognosis of oral cancer (OC). Methods We performed a systematic review and meta‐analysis to clarify this issue. Data searches were performed using PubMed, Web of Science, Epistemonikos, and Embase databases through November 2019. The primary outcome was the difference in the prognosis of OC between BQ‐AN chewers and non‐chewers, measured in terms of 5‐year overall survival (OS) and 5‐year disease‐specific survival (DSS) log (HR) reported in articles. The pooled HR with 95% CI of 5‐year OS and 5‐year DSS was calculated using a fixed‐effects model. Results Ten articles with eleven OS or DSS survival studies (one of the articles contained two studies), which were published between 2003 and 2017, were eligible for inclusion in the present study. All the 11 studies were observational studies, among which 10 were retrospective and 1 was prospective. One study measured both OS and DSS. Eight studies, with a total of 2,761 patients, used 5‐year OS as the primary endpoint and four studies, with a total of 2,551 patients, used 5‐year DSS. Overall, the pooled HR evaluating BQ‐AN chewers was 1.26 (95% CI: 1.09–1.46) for 5‐year OS and 1.40 (95% CI: 1.15–1.70) for 5‐year DSS, compared with non‐chewers. There was a significant association between BQ‐AN chewing and OC survival. Conclusions Betel quid and areca nut chewing is significantly associated with poor prognosis in patients with OC.

show abstract

“… 5 The global incidence of OSCC is 3.90 per 100 000, while the global mortality of oral cancer is 1.94 per 100 000. 6 , 7 The 5-year overall survival rate for OSCC related to carcinogens is no more than 60%. 8 Except for some early-stage OSCC, which is only treated with surgery, the treatment of most OSCC cases requires a multi-modal approach.…”

Section: Introductionmentioning

confidence: 99%

The Current Landscape of Oral Squamous Cell Carcinoma: A Comprehensive Analysis from ClinicalTrials.gov

Zou

Wen

et al. 2022

Cancer Control

View full text Add to dashboard Cite

Objective A better understanding of the current characteristics of clinical trials in oral squamous cell carcinoma (OSCC) is important to improve trial design and identify neglected areas of research. The objective is to summarize the current characteristics and publication status of OSCC trials registered on ClinicalTrials.gov. Methods The ClinicalTrials.gov database was searched on November 9, 2020, for trials containing the term “oral squamous cell carcinoma”. We assessed the characteristics of the included trials and searched the publication status of the primary completed trials by using PubMed and Google Scholar. Results Our search identified 325 studies for analysis, including 279 interventional (85.8%) and 46 observational (14.2%) studies. Interventional studies were mostly single-group (50.9%), single-center (57.0%), non-randomized (59.1%), open-label (81.4%), and early-phase (70.6%) trials. The vast majority of the studies (82.8%) focused on the treatment of OSCC. Chemotherapy (36.8%) was the most common treatment, followed by targeted therapy (15.2%) and immunotherapy (15.2%). Furthermore, 58.9% of the primary completed interventional studies were published by January 8, 2021, and the median time to publication was 48.0 months. Studies registered before this study began (HR = 1.69, 95% CI = 1.02–2.80, P = .040) and in phases 1/2 or 2 (HR = 2.10, 95% CI = 1.09–4.06, P = .026) were associated with an improved likelihood of publication. Conclusions OSCC clinical trials usually have small sample size and are open-label and non-randomized studies. Advanced OSCC and immunotherapy-oriented therapy are becoming the focus of current trials. Researchers should perform standardized registration and publish their results in a timely manner.

show abstract

Analysis of risk factors for multiple primary oral squamous cell carcinoma: a cohort study

Cited by 14 publications

References 51 publications

Chemical Composition, Pharmacological, and Toxicological Effects of Betel Nut

Chemical Composition, Pharmacological, and Toxicological Effects of Betel Nut

Do betel quid and areca nut chewing deteriorate prognosis of oral cancer? A systematic review, meta‐analysis, and research agenda

The Current Landscape of Oral Squamous Cell Carcinoma: A Comprehensive Analysis from ClinicalTrials.gov

Contact Info

Product

Resources

About